Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Secondary progressive multiple sclerosis: current knowledge and future challenges.

Marco Rovaris1, Christian Confavreux, Roberto Furlan

  • 1Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy.

The Lancet. Neurology
|March 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

PloS one·2016
Same author

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Neurology(R) neuroimmunology & neuroinflammation·2016
Same author

History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.

Neurology·2016
Same author

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Multiple sclerosis (Houndmills, Basingstoke, England)·2016
Same author

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Multiple sclerosis (Houndmills, Basingstoke, England)·2016
Same author

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Journal of neurology·2016
Same journal

Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

The Lancet. Neurology·2026
Same journal

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
See all related articles

Secondary progressive multiple sclerosis (MS) progression is poorly understood, likely driven by neurodegeneration over inflammation. New treatments focusing on neuroaxonal repair are crucial for managing this MS phase.

Area of Science:

  • Neuroscience
  • Neurology
  • Immunology

Background:

  • Secondary progressive multiple sclerosis (MS) is characterized by steady disability accrual.
  • The mechanisms driving the transition from relapsing-remitting MS to SPMS are not well understood.
  • Current immunomodulating treatments show limited efficacy in later stages of SPMS.

Purpose of the Study:

  • To explore the underlying mechanisms of the transition to secondary progressive multiple sclerosis.
  • To evaluate the efficacy of current treatments in different stages of MS.
  • To identify potential predictors for the transition to progressive MS.

Main Methods:

  • Review of epidemiological and neuroimaging studies.
  • Analysis of the efficacy of immunomodulating and immunosuppressive therapies.

Related Experiment Videos

  • Discussion of the role of neurodegenerative versus inflammatory changes.

    • Main Results:

    • Evidence suggests neurodegeneration plays a larger role than inflammation in SPMS.
    • Available treatments have diminished efficacy in advanced SPMS.
    • No clear clinical or paraclinical predictors for the transition to SPMS have been identified.

    Conclusions:

    • The transition to SPMS is likely driven by neurodegenerative processes.
    • Developing treatments that promote neuroaxonal repair is a critical unmet need for SPMS.
    • Quantitative MRI measures are valuable for monitoring SPMS in research and clinical trials.